Shares of other companies:
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
April 26, 2024 Top 10 High Dividend Yield Stocks
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
Tesla Is An AI Company That The Market Won’t Reward For Now
April 24, 2024
Amazon: The Margin Train Is Gaining Speed
April 24, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
NVAX Stock News and Mentions of Novavax, Inc. Stocktwits
Updated: April 27, 2024 (09:14)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Novavax Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Novavax, Inc. (NVAX).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Novavax stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Novavax, Inc. (NVAX)
April 22, 2024 (18:39) / "Zacks Commentary" (by Zacks Equity Research)
How Should You Play Merck ( MRK ) Stock Ahead of Q1 Earnings?
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports first-quarter 2024 earnings.
In Article Trend: Somewhat-Bullish
April 22, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
In Article Trend: Bullish
April 21, 2024 (09:08) / "Motley Fool" (by Adria Cimino)
These Biotech Stocks Could Soar 120% and 295%, According to Wall Street
Catalysts lie ahead for both of these companies.
In Article Trend: Somewhat-Bullish
April 19, 2024 (13:39) / "Zacks Commentary" (by Zacks Equity Research)
What's in Store for Biogen ( BIIB ) This Earnings Season?
Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been moderate.
In Article Trend: Neutral
April 15, 2024 (13:14) / "Benzinga" (by Adam Eckert)
What's Going On With Novavax Stock Today? - Novavax ( NASDAQ:NVAX )
Novavax Inc NVAX shares are trading higher Monday after Shah Capital Management reported a 6.66% stake in the company and nominated two directors for the company's board.
In Article Trend: Neutral
April 15, 2024 (10:00) / "Benzinga" (by Globe Newswire)
Shah Capital nominates two highly qualified independent director candidates for Novavax - Novavax ( NASDAQ:NVAX )
RALEIGH, N.C., April 15, 2024 ( GLOBE NEWSWIRE ) -- Shah Capital, which owns approximately 6.7% of the outstanding common stock of Novavax NVAX, has today issued the below statement:
In Article Trend: Somewhat-Bullish
)
April 15, 2024 (05:20) / "Business Standard" (by Reuters)
US-based Hedge fund Shah Capital urges Novavax board shake-up: Report
US-based hedge fund Shah Capital wrote to the Novavax board on Monday to push for the instalment of two new independent directors, the Financial Times reported on Monday.
In Article Trend: Somewhat-Bearish
April 14, 2024 (10:18) / "Forbes" (by Katherine Hignett)
England Launches Latest Round Of Covid-19 Booster Vaccines
England has launched its latest Covid-19 booster campaign for those at the highest risk from the disease. From Monday, people over the age of 75, those who live in adult care homes and others with certain underlying health conditions will be able to book a free shot to boost their protection ...
In Article Trend: Neutral
April 13, 2024 (20:22) / "Motley Fool" (by Prosper Junior Bakiny)
Better Buy: Bluebird Bio Vs. Novavax
Who wins this face-to-face between two beaten-down biotechs?
In Article Trend: Somewhat-Bullish
April 13, 2024 (05:09) / "Canada Newswire"
All International Medical Approval News and Press Releases from Cision Canada
VANCOUVER, BC, April 5, 2024 /CNW/ - Asep Medical Holdings Inc. ( "Asep" or the "Company" ) ( CSE: ASEP ) ( OTCQB: SEPSF ) ( FSE: JJ8 ) is very pleased to... MONTREAL, March 25, 2024 /CNW/ - Innodem Neurosciences, a leading digital health and AI company, announced today that its ...
In Article Trend: Somewhat-Bullish
April 12, 2024 (13:09) / "Zacks Commentary" (by Zacks Equity Research)
J&J ( JNJ ) to Begin Pharma Q1 Earnings Season: What's in Store?
J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.
In Article Trend: Somewhat-Bullish
April 12, 2024 (10:35) / "Motley Fool" (by David Jagielski)
Down 60% From Its 52-Week High, Is Novavax Stock a Buy?
Is there still too much risk surrounding this business?
In Article Trend: Neutral
April 11, 2024 (13:12) / "Zacks Commentary" (by Zacks Equity Research)
Will Novavax's ( NVAX ) Strategic Reshaping Curb Cash Burn?
To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.
In Article Trend: Neutral
April 3, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
In Article Trend: Bullish
April 2, 2024 (14:15) / "Motley Fool" (by Prosper Junior Bakiny)
1 Beaten-Down Stock to Buy and 1 to Avoid Like the Plague
These stocks could move in very different directions over the long run.
In Article Trend: Somewhat-Bullish
March 29, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)
Novavax ( NVAX ) Down 3.2% Since Last Earnings Report: Can It Rebound?
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 27, 2024 (16:24) / "Zacks Commentary" (by Zacks Equity Research)
Moderna ( MRNA ) Posts Upbeat Data From Next-Gen COVID Jab Study
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID vaccine induces a more robust immune response compared with its previously approved bivalent COVID vaccine.
In Article Trend: Neutral
March 21, 2024 (01:24) / "Money Control"
Wall Street ends higher as Fed keeps three rate cuts on the horizon
The Fed's policy statement described inflation as remaining "elevated," and it raised economic projections for economic growth and lowered its projection for the unemployment rate from estimates it provided in December.
In Article Trend: Neutral
March 20, 2024 (17:07) / "Investors Business Daily" (by Investor's Business Daily)
Is Pfizer Stock, At A Nine-Year Low, A Sell Amid The Search For Its Big Break?
Pfizer ( PFE ) stock is trading at its lowest point in nine years as the drugmaker looks for its next big break after developing the first Covid vaccine with Germany's BioNTech ( BNTX ) . This month, the European Commission approved Pfizer's Prevnar 20, a vaccine to help protect babies and ...
In Article Trend: Neutral
March 20, 2024 (13:09) / "Investors Business Daily" (by Investor's Business Daily)
BioNTech Dives As Sales Crash 65%, Missing Forecasts
BioNTech Stock Dives After Sales Plummet 65% And Miss Forecasts Investor's Business Daily ...
In Article Trend: Neutral
March 15, 2024 (14:45) / "Benzinga" (by Benzinga Insights)
( NVAX ) - Analyzing Novavax's Short Interest - Novavax ( NASDAQ:NVAX )
Novavax's NVAX short percent of float has risen 5.26% since its last report. The company recently reported that it has 54.83 million shares sold short, which is 55.43% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.1 days to cover their ...
In Article Trend: Somewhat-Bullish
March 13, 2024 (10:12) / "Motley Fool" (by Adria Cimino and Keith Speights)
Moderna Stock: Bull vs. Bear
This stock delivered spectacular gains in the past.
In Article Trend: Neutral
March 9, 2024 (06:59) / "Motley Fool" (by Prosper Junior Bakiny)
1 Beaten-Down Stock That's Still Not Worth Buying
For this biotech, a rebound seems far too unlikely.
In Article Trend: Neutral
March 7, 2024 (10:28) / "Motley Fool" (by Adria Cimino)
Two Beaten-Down Stocks That Could Soar 170% and 630%, Respectively, According to Wall Street
Could these biotech companies still win in the vaccine market and beyond?
In Article Trend: Neutral
March 6, 2024 (17:08) / "CNBC" (by Annika Kim Constantino)
Healthy Returns: What to know about CDC's new Covid recommendations
The CDC announced two new major Covid recommendations last week. Meanwhile, venture firm General Catalyst said it was buying Summa Health.
In Article Trend: Neutral
March 5, 2024 (17:10) / "Motley Fool" (by Motley Fool Staff)
Goodbye, Project Titan
We also talk with Carrie Sun, author of "Private Equity," for a behind-the-scenes look at life at a hedge fund.
In Article Trend: Neutral
March 4, 2024 (10:03) / "Motley Fool" (by Adria Cimino)
Is Novavax a Buy Now?
The stock has dropped 98% over the past three years.
In Article Trend: Somewhat-Bullish
March 1, 2024 (10:25) / "Motley Fool" (by David Jagielski)
1 of the Biggest Risks Facing Novavax Has Now Been Resolved: Is Now the Time to Buy the Stock?
Can the stock's recent rally continue?
In Article Trend: Neutral
February 29, 2024 (16:12) / "Zacks Commentary" (by Zacks Equity Research)
Novavax ( NVAX ) Q4 Earnings & Sales Miss Estimates, Stock Tanks
Novavax's (NVAX) fourth-quarter earnings and revenues miss estimates. Stock tanks on moderate revenue guidance for 2024.
In Article Trend: Neutral
February 28, 2024 (15:52) / "Benzinga" (by Vandana Singh)
Why Is Novavax Stock Trading Lower Today? - Novavax ( NASDAQ:NVAX )
Wednesday, Novavax Inc NVAX reported fourth-quarter 2023 revenues of $291 million, down from $357 million a year ago, missing the consensus of $321.97 million. Total revenue for 2023 was $984 million, compared to $2 billion in the same period in 2022.
In Article Trend: Somewhat-Bullish
February 28, 2024 (15:25) / "Business Standard" (by Reuters)
Still facing strong headwinds, 2024 sales flat to lower, says Novavax | World News
Still facing strong headwinds, 2024 sales flat to lower, says Novavax Business Standard ...
In Article Trend: Neutral
February 28, 2024 (14:10) / "Zacks Commentary" (by Zacks Equity Research)
Novavax ( NVAX ) Reports Q4 Loss, Lags Revenue Estimates
Novavax (NVAX) delivered earnings and revenue surprises of -193.88% and 12.89%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
February 28, 2024 (13:00) / "CNBC" (by Annika Kim Constantino)
Novavax misses quarterly estimates, but vaccine maker narrows losses as it slashes costs
Novavax narrowed its losses in the quarter compared to the same period a year ago, even as demand for Covid products continues to plummet worldwide.
In Article Trend: Neutral
February 28, 2024 (02:06) / "Benzinga" (by Benzinga Neuro)
BYND, NVAX, VKTX, BIDU, TSLA: Top 5 Trending Stocks Today - Beyond Meat ( NASDAQ:BYND ) , Baidu ( NASDAQ:BIDU )
On Tuesday, the U.S. indices exhibited a varied performance, as the S&P 500 rose by nearly 0.2% to reach 5,078.18, while the Dow Jones Industrial Average dipped by 0.25% to settle at 38,972.41. Concurrently, the Nasdaq experienced a nearly 0.4% increase, reaching 16,035.30.
In Article Trend: Somewhat-Bullish
February 27, 2024 (10:30) / "Motley Fool" (by Adria Cimino)
Has Novavax Just Solved Its Biggest Problem?
The biotech company recently settled a dispute with a major customer.
In Article Trend: Neutral
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website